Cabaletta Bio Inc. Common Stock (CABA)
Stock · NASDAQ · Health Care
$3.11as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta100.0%
Support level
$2.73
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 154
- Website
- www.cabalettabio.com/
Fundamentals
- 1-day range
- $3.11$3.37
- Market cap
- $450.03M
- P/E (trailing)
- —
- P/E (forward)
- -2.11
- EPS (trailing)
- $-1.96
- Dividend yield
- —
- Beta
- 3.47
- Avg. volume
- 4.67M
52-week range
$1.4$4.23
Next earnings: November 16, 2026 · EPS estimate $-0.31Before Openconfirmed
Forecasts
8 analyst ratings
Buy 81%
Hold 19%
Sell 0%
1-year price forecast
High
$30
+864.6%
Median
$13.5
+334.1%
Low
$3
-3.5%
Cabaletta Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CABACabaletta Bio Inc. Common Stock$3.11▼ 7.99%Market cap $450.03MP/E —$1.4$4.23
- KYTXKyverna Therapeutics Inc. Common Stock$8.36▼ 3.24%Market cap $471.16MP/E —$3.55$13.67
- OCGNOcugen Inc. Common Stock$1.32▼ 3.65%Market cap $420.50MP/E —$1$2.73
- SCTXScribe Therapeutics Inc. Common Stock$28.44▼ 1.39%Market cap $411.18MP/E —
- VALNValneva SE American Depositary Shares$6.43▼ 2.13%Market cap $491.51MP/E —$2.03$5.34
- PROKProKidney Corp. Class A Ordinary Shares$1.84▲ 1.10%Market cap $495.38MP/E —$1.3$3.48
- STROSutro Biopharma Inc. Common Stock$20.42▼ 4.18%Market cap $400.18MP/E —$7.15$43.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CABA Cabaletta Bio Inc. Common Stock | $450.03M | — | $3.11 | ▼ 7.99% | $1.4$4.23 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $8.36 | ▼ 3.24% | $3.55$13.67 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $1.32 | ▼ 3.65% | $1$2.73 |
| SCTX Scribe Therapeutics Inc. Common Stock | $411.18M | — | $28.44 | ▼ 1.39% | |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $6.43 | ▼ 2.13% | $2.03$5.34 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.84 | ▲ 1.10% | $1.3$3.48 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $20.42 | ▼ 4.18% | $7.15$43.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3benzinga · 8/14/2026
- Adicet Bio: A Cheap Gamma Delta T-Cell PlaySeekingAlpha · 8/14/2026
- Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3Benzinga · 8/14/2026
- Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) EstimateBenzinga · 8/13/2026
Insider Activity
Insider Actions →Acquired
1.81M
Disposed
0
- Catherine Bollard · June 9, 2026 · Grant22.0K
- Brun Scott C. · June 9, 2026 · Grant22.0K
- Shawn Tomasello · June 9, 2026 · Grant22.0K
- Mark Simon · June 9, 2026 · Grant22.0K
- HENRIQUES RICHARD C JR · June 9, 2026 · Grant22.0K
- Das Arun · March 2, 2026 · Grant175.0K
- Michael Gerard · March 2, 2026 · Grant175.0K
- Gwendolyn Binder · March 2, 2026 · Grant225.0K
- David J. Chang · March 2, 2026 · Grant225.0K
- Marda Anup · March 2, 2026 · Grant225.0K
- Steven Nichtberger · March 2, 2026 · Grant674.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 86.33M
- Total value held
- $199.28M
- Institutional holders
- 108
Top holders this quarter
- Unknown11.08M
- Unknown9.68M
- Unknown8.97M
- Unknown8.83M
- Unknown5.90M
- Unknown5.50M
- Unknown4.03M
- Unknown2.50M
- Unknown2.37M
- Unknown2.18M
See the full, filterable feed with live charts on the MarketWall dashboard.